Organovo signs drug discovery agreement with J & J unit


Shares of Organovo (NYSEMKT:ONVO) are up 17% premarket on robust volume in response the signing of a research agreement with Johnson & Johnson unit Janssen Research and Development to evaluate the use of 3D bio-printed tissue in drug discovery. Financial terms are not disclosed.

From other sites
Comments (9)
  • ECapo
    , contributor
    Comments (735) | Send Message
     
    ONVO is moving closer to the release and soon the stock will jump to all new time highs.
    24 Jul 2014, 09:35 AM Reply Like
  • Mukticat
    , contributor
    Comments (2074) | Send Message
     
    Yawn. Just one more of their revenue-less 'deals' that leads to . . . nothing.

     

    Rarely has a company seen such few results in so much time.
    24 Jul 2014, 10:03 AM Reply Like
  • flyer777
    , contributor
    Comments (24) | Send Message
     
    If it was easy everyone would be doing it.
    24 Jul 2014, 03:50 PM Reply Like
  • betchewiwin
    , contributor
    Comments (55) | Send Message
     
    Try SZYM if you think ONVO is bad.....
    24 Jul 2014, 06:32 PM Reply Like
  • lifestock
    , contributor
    Comments (26) | Send Message
     
    You couldn't be more wrong Mukticat. Organovo has held strong on their release date of their first product. Once this product is released we will see the potential Organovo has financially.
    24 Jul 2014, 11:44 AM Reply Like
  • Theodore Savas
    , contributor
    Comments (148) | Send Message
     
    I don't know how long it will take to establish itself, but I have no doubt 3D printing has a strong future in the medical research and development field. In some ways it seems far-fetched, but so does nearly everything until it is commonplace. I have my position in the stock and I am holding.
    24 Jul 2014, 11:49 AM Reply Like
  • Poynter
    , contributor
    Comments (38) | Send Message
     
    I also agree. Bio-printing organs is in the near term an absurd proposition, but bio-printing small samples of living tissue, with realistic cytoarchitecture is achievable and has huge application in medicine, stem cell R&D, and materials science engineering.
    24 Jul 2014, 12:59 PM Reply Like
  • xdentist
    , contributor
    Comments (18) | Send Message
     
    I completely agree with you, Mr. {I assume it's Mr.} Savas.
    24 Jul 2014, 12:13 PM Reply Like
  • flyer777
    , contributor
    Comments (24) | Send Message
     
    From reading the filing it seems that Janssen R&D is moving beyond the current product and is exploring the potential to move into other types of organ tissue (heart, lung, etc..
    "the use of 3D bio-printed tissue in a drug discovery setting, outside of the Company's work in 3D liver tissue for toxicity testing."
    No matter how you look at this it is further validation of Organovo's technology.
    25 Jul 2014, 09:55 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs